An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Thiolloy, Sophie ^a   Edwards, James R ^b   Fingleton, Barbara ^a   Rifkin, Daniel B ^c   Matrisian, Lynn M ^a   Lynch, Conor C ^d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD11B ANTIGEN; GELATINASE A; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PURIFICATION; APOPTOSIS; ARTICLE; BIOAVAILABILITY; BONE METASTASIS; CANCER CELL; CANCER CONTROL; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; EX VIVO STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BONE; BONE TUMOR; CELL CULTURE; CELL STRAIN COS1; CERCOPITHECUS; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; METASTASIS; MICRO-COMPUTED TOMOGRAPHY; MOUSE MUTANT; NEOPLASM; PATHOLOGY; PHYSIOLOGY; RADIOGRAPHY;

MURINAE; MUS;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NEOPLASMS; OSTEOBLASTS; TRANSFORMING GROWTH FACTOR BETA; X-RAY MICROTOMOGRAPHY;

EID: 84855392626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029862     Document Type: Article

References (64)

1. Coleman RE, Rubens RD, (1987) The clinical course of bone metastases from breast cancer. British Journal of Cancer 55: 61-66.
2. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, et al. (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14: 6387-6395.
3. Mundy GR, (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer 2: 584-593.
4. Martin T, Gooi JH, Sims NA, (2009) Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr 19: 73-88.
5. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
6. Kakonen SM, Mundy GR, (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97: 834-839.
7. Teitelbaum SL, (2000) Bone resorption by osteoclasts. Science 289: 1504-1508.
8. Guise TA, (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88: 2892-2898.
9. Compston JE, (2002) Bone marrow and bone: a functional unit. J Endocrinol 173: 387-394.
10. Vaes G, (1972) The release of collagenase as an inactive proenzyme by bone explants in culture. Biochem J 126: 275-289.
11. Delaisse JM, Engsig MT, Everts V, del Carmen O, Ferreras M, et al. (2000) Proteinases in bone resorption: obvious and less obvious roles. Clinica Chimica Acta 291: 223-234.
12. Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, et al. (2005) The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci 118: 147-156.
13. Breckon JJ, Papaioannou S, Kon LW, Tumber A, Hembry RM, et al. (1999) Stromelysin (MMP-3) synthesis is up-regulated in estrogen-deficient mouse osteoblasts in vivo and in vitro. Journal of Bone and Mineral Research 14: 1880-1890.
14. Inoue K, Mikuni-Takagaki Y, Oikawa K, Itoh T, Inada M, et al. (2006) A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem 281: 33814-33824.
15. Lynch CC, (2010) Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone.
16. Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, et al. (2007) Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 16: 1113-1123.
17. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, et al. (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7: 485-496.
18. Thiolloy S, Halpern J, Holt GE, Schwartz HS, Mundy GR, et al. (2009) Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res 69: 6747-6755.
19. Halpern J, Lynch CC, Fleming J, Hamming D, Martin MD, et al. (2006) The application of a murine bone bioreactor as a model of tumor: bone interaction. Clin Exp Metastasis 23: 345-356.
20. Martin M, Carter K, Thiolloy S, Lynch CC, Matrisian L, et al. (2008) Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68: E-Pub ahead of print.
21. Guise TA, Chirgwin JM, (2003) Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res pp. S32-38.
22. Prudova A, Auf dem Keller U, Butler GS, Overall CM, (2010) Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics.
23. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J, (1999) Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 10: 99-117.
24. Dallas SL, Rosser JL, Mundy GR, Bonewald LF, (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277: 21352-21360.
25. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF, (1995) Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131: 539-549.
26. Yu Q, Stamenkovic I, (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes and Development 14: 163-176.
27. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, et al. (2006) Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25: 3408-3423.
28. Dybedal I, Guan F, Borge OJ, Veiby OP, Ramsfjell V, et al. (1997) Transforming growth factor-beta1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells. Blood 90: 3395-3403.
29. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R, (1995) Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270: 10618-10624.
30. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J, (1999) Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action 2. Cytokine Growth Factor Rev 10: 99-117.
31. Dabovic B, Chen Y, Colarossi C, Zambuto L, Obata H, et al. (2002) Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation. J Endocrinol 175: 129-141.
32. Chen Y, Dabovic B, Annes JP, Rifkin DB, (2002) Latent TGF-beta binding protein-3 (LTBP-3) requires binding to TGF-beta for secretion. FEBS Lett 517: 277-280.
33. Dabovic B, Chen Y, Colarossi C, Obata H, Zambuto L, et al. (2002) Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability. J Cell Biol 156: 227-232.
34. Dabovic B, Levasseur R, Zambuto L, Chen Y, Karsenty G, et al. (2005) Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient mice. Bone 37: 25-31.
35. Penttinen C, Saharinen J, Weikkolainen K, Hyytiainen M, Keski-Oja J, (2002) Secretion of human latent TGF-beta-binding protein-3 (LTBP-3) is dependent on co-expression of TGF-beta. J Cell Sci 115: 3457-3468.
36. Dean RA, Overall CM, (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 6: 611-623.
37. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H, (1994) Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. Journal Biological Chemistry 269: 25742-25746.
38. Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, et al. (1995) Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136: 3527-3533.
39. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, et al. (2008) EphrinB2 Regulation by Parathyroid Hormone (PTH) and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts. J Bone Miner Res.
40. Fiore E, Fusco C, Romero P, Stamenkovic I, (2002) Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21: 5213-5223.
41. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, et al. (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58: 1048-1051.
42. Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, et al. (2004) Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Research 64: 652-658.
43. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, et al. (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. Journal of Clinical Investigation 99: 2509-2517.
44. Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, et al. (2006) Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. International Journal of Cancer 118: 2721-2726.
45. Nabha SM, Bonfil RD, Yamamoto HA, Belizi A, Wiesner C, et al. (2006) Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis. Clin Exp Metastasis 23: 335-344.
46. Janssens K, Ten Dijke P, Janssens S, Van Hul W, (2005) Transforming growth factor-beta1 to the bone. EndocrRev 26: 743-774.
47. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF, (1995) Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131: 539-549.
48. Maeda S, Dean DD, Gay I, Schwartz Z, Boyan BD, (2001) Activation of latent transforming growth factor beta1 by stromelysin 1 in extracts of growth plate chondrocyte-derived matrix vesicles. Journal of Bone and Mineral Research 16: 1281-1290.
49. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD, (2002) The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcified Tissue International 70: 54-65.
50. Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, et al. (1999) Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126: 4267-4279.
51. Ge G, Greenspan DS, (2006) BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 175: 111-120.
52. Todorovic V, Frendewey D, Gutstein DE, Chen Y, Freyer L, et al. (2007) Long form of latent TGF-beta binding protein 1 (Ltbp1L) is essential for cardiac outflow tract septation and remodeling. Development 134: 3723-3732.
53. Koli K, Wempe F, Sterner-Kock A, Kantola A, Komor M, et al. (2004) Disruption of LTBP-4 function reduces TGF-beta activation and enhances BMP-4 signaling in the lung. J Cell Biol 167: 123-133.
54. Sterner-Kock A, Thorey IS, Koli K, Wempe F, Otte J, et al. (2002) Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev 16: 2264-2273.
55. Urban Z, Hucthagowder V, Schurmann N, Todorovic V, Zilberberg L, et al. (2009) Mutations in LTBP4 cause a syndrome of impaired pulmonary, gastrointestinal, genitourinary, musculoskeletal, and dermal development. Am J Hum Genet 85: 593-605.
56. Cowell S, Knauper V, Stewart ML, D'Ortho MP, Stanton H, et al. (1998) Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 331 (Pt 2): 453-458.
57. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, et al. (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS 107: 38-44.
58. Holmbeck K, Bianco P, Chrysovergis K, Yamada S, Birkedal-Hansen H, (2003) MT1-MMP-dependent, apoptotic remodeling of unmineralized cartilage: a critical process in skeletal growth. J Cell Biol 163: 661-671.
59. Juarez P, Guise TA, (2010) TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone 48: 23-29.
60. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, et al. (2001) Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone MinerRes 16: 1787-1794.
61. Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, et al. (2001) Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet 28: 261-265.
62. Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, et al. (2010) Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res 26: 2523-2536.
63. Harrell PC, McCawley LJ, Fingleton B, McIntyre JO, Matrisian LM, (2005) Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. Exp Cell Res 303: 308-320.
64. Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, et al. (1990) The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol 145: 1415-1422.